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Ségolène Aymé* and Charlotte RodwellAbstract
The European Union Committee of Experts on Rare Diseases was entrusted with aiding the European Commission
in a number of tasks, ranging from the monitoring of initiatives, to recommending improvements and actions to be
pursued in the future, in addition to helping strengthen liaison at both European and International levels in the
field of rare diseases. The three-year mandate of the EUCERD drew to a close in July 2013 with an impressive record.
The EUCERD has laid down the foundations for future work so as to continue to advance in the key areas that
have been identified as of interest for the rare disease community at large: centres of expertise, European
Reference Networks, patient registries and databases, newborn screening, and indicators for national rare disease
plans/strategies. The work of the Committee should now be continued by the newly formed European Commission
Expert Group on Rare Diseases.
Keywords: European policy, Recommendations, National plans/strategies for rare diseases, Centres of expertise,
Access to orphan medicinal products, Patient registries, European reference networksIntroduction
The three-year mandate of the European Union Com-
mittee of Experts on Rare Diseases [1] drew to a close in
July 2013 with an impressive record. These results were
achieved thanks to the unique nature of the forum it
provided for the discussion of key topics for the rare dis-
ease community, bringing together representatives from
all 28 European Member States, experts, patient repre-
sentatives and members of the Industry, as well as the
European Commission [Figure 1]. The enthusiastic par-
ticipation of the 51 members of the EUCERD allowed
the EUCERD to foster exchanges of relevant experience,
policies and practices in the field of rare diseases, and
help the European Commission and the Member States
prepare and implement activities in the in the field of
rare diseases.
Established via the European Commission Decision of
30 November 2009 (2009/872/EC) [2], the EUCERD
responded quickly to the evolving needs of the rare dis-
ease community [Figure 2] following the Commission* Correspondence: segolene.ayme@inserm.fr
INSERM, US14 - Orphanet, Paris, France
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article, unless otherwise stated.Communication Rare Diseases: Europe’s Challenge (2008)
[3] and the Council Recommendation on an Action in
the Field of Rare Diseases (2009) [4]. These texts defined
a European policy in the field and notably encouraged
Member States to elaborate national plans/strategies
for rare diseases by the end of 2013 to “[guide] and
[structure] relevant actions in the field of rare diseases
within the framework of their health and social
systems”. Although other non-European countries and
world regions have policies in place relative to orphan
medicinal products, Europe is the only region with a
public health policy in the field of rare diseases.
The EUCERD selected from the key areas cited by the
Commission Communication and Council Recommenda-
tion a number of topics which had to be tackled immedi-
ately in order to clarify concepts and guide the reflection
underway at national level. Most of these selected topics
had already been tackled by the European Commission’s
Rare Diseases Task Force (RDTF), the EUCERD’s prede-
cessor, and there was sufficient consensus to elaborate sets
of recommendations for the European Commission and
Member States. Supported via two consecutive Joint Ac-
tions between Member States (N°2008 22 91 and N°2011entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Composition of the EUCERD.
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workshops over the years to elaborate the recommenda-
tions in areas concerning the organisation of expert
services (centres of expertise and European Reference
Networks), data collection, and access to medicines. For
each topic the process started with the identification of
the scope of the issue and a fact-finding mission concern-
ing the state of the art of the topic. This information wasFigure 2 Evolution of concepts and initiatives in the field of rare diseused to produce a preliminary report, or a draft recom-
mendation, which provided material in turn for an expert
workshop to discuss and elaborate a recommendation
which was then submitted for discussion and adoption by
the EUCERD [Figure 3]. The Recommendations have been
disseminated by the members of the Committee and
through OrphaNews Europe [5], the newsletter of the
committee with 14 000 registered readers.ases in Europe.
Figure 3 The EUCERD’s work process.
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strategies for rare diseases and a step towards European
networks
The first area of the Council Recommendation to be dealt
with by the Committee concerned the centres of expertise
for rare diseases and European Reference Networks for
rare diseases. The identification, and creation, of centres
of expertise for rare disease is a key element of the Council
Recommendation and central to national rare disease
plans/strategies. There are around 6 000 rare diseases and
most are unknown to healthcare professionals so rarediseases patients suffer from not knowing where to con-
sult. To overcome this, some Member States have estab-
lished centres specialised in some rare diseases/groups of
rare diseases which have proven to be very efficient in
providing quality of care for patients. The networking of
these centres could lead to the gathering of the scarce ex-
pertise concerning these diseases at European level, in
order to ensure equal access to accurate information, ap-
propriate and timely diagnosis and high quality care for
rare disease patients.
This area had been previously identified by the former
RDTF as a priority topic with a dedicated working
group, as networks of centres of expertise had been de-
fined by the High Level Working Group on European
Centres of Expertise as an area of European added-value
with consensus on the benefits of a cross-border ap-
proach [6]. Indeed, the RDTF had previously established
a list of criteria for designation of centres of expertise
which served as the starting point for the EUCERD’s re-
flection on this subject. Currently, the organisation of
centres of expertise varies greatly from country to coun-
try: few countries currently have a designation process
in place, and the designation criteria vary across these
countries, and sometimes even from region to region. By
revisiting the work of the RDTF, the EUCERD was able
to draft and adopt recommendations relevant to the
current situation concerning the definition of the mis-
sions, scope and criteria for designation and evaluation
of centres of expertise. The EUCERD’s Quality Criteria
for Centres of Expertise for Rare Diseases in Member
States (2011) [7] have been very well received in the EU
Member States and are being actively used as a starting
point in the elaboration of the actions concerning the
organisation of care in their national plans/strategies.
Member States have appreciated the clarification of con-
cepts provided by the Recommendations which can be tai-
lored to the countries’ specificities. It is hoped that the use
of these Recommendations will help to harmonise the cri-
teria for designation of centres from country to country,
in preparation for the establishment of the future
European Reference Networks for rare diseases, for which
centres of expertise are the building blocks [Table 1].
European Reference Networks for rare diseases: the
European dimension of health care pathways
Collaboration of centres of expertise through European
Reference Networks (ERNs) is highlighted in the Council
Recommendation, whilst the creation of such European
structures is a key element of the Directive on the appli-
cation of patients’ rights in cross-border healthcare
(2011/24/EU) (9 March 2011) [8], which specifically cites
rare diseases as an area of interest for ERNs. The con-
cept of ERNs for rare diseases had been developed over
a number of years before the creation of the EUCERD
Table 1 Key facts and state of play in European countries
in December 2013: Centres of expertise for rare diseases
(CE RD)1
• 1 European country with designated CE RD in the scope of a national
plan for rare diseases
• 5 European countries with officially designated CE RD
• 15 European countries with non-designated CE RD acknowledged by
health authorities to varying degrees
• 9 European countries with CE RD recognised by reputation only
• 16 European countries with plans to designate CE RD in their
national plans/strategies for RD
• EUCERD Recommendations on quality criteria for centres of expertise
for rare diseases in Member States adopted on 24 October 2011
• Consensus on 45 recommendations covering the mission and scope,
criteria for designation, process of designation and evaluation, and
European dimension of CE RD
1Data as of December 2013, reproduced from S. Aymé, C. Rodwell (eds.), 2014
Report on the State of the Art of Rare Disease Activities in Europe, to be
published in July 2014.
Table 2 Key facts : European Reference Networks (ERNs)
for rare diseases
• Rare diseases cited in Directive on the application of patients’ rights
in cross border healthcare (2011/24/EU) (9 March 2011) as priority
area for ERNs
• EUCERD Recommendations on European Reference Networks for Rare
Diseases adopted on 31 January 2013
• Consensus on 21 recommendations covering mission, vision and
scope, governance, composition, funding and evaluation, and
designation of ERNs for Rare Diseases
Aymé and Rodwell Orphanet Journal of Rare Diseases 2014, 9:30 Page 4 of 7
http://www.ojrd.com/content/9/1/30by a dedicated RDTF working group mandated by the
HLG. This working group ascertained that the treatment
of rare diseases demands multidisciplinary care which
is sometimes not available at local or national level
and worked on establishing a set of recommendations
concerning ERNs [9]. The EUCERD decided, once the
concept of centres of expertise was well established,
to take stock of this work in the context of the Directive
in order to establish a recommendation for both the
European Commission and the Member States. The Rec-
ommendations on European Reference Networks for Rare
Diseases (2013) [10] highlights the specificities of rare
diseases to be taken into account when considering the
scope, mission, governance, designation and evaluation
of such ERNs in the future activities planned around the
Cross-Border Healthcare Directive. The reflections dur-
ing the elaboration of the document have helped develop
the concept of ERNs in the field of rare diseases. The
adopted EUCERD Recommendations have provided
guidance to Member States in process of elaborating the
healthcare pathways at both the national and European
levels in the scope of their national plans/strategies for
rare diseases to ensure that this future possibility is
envisaged from their inception. The Recommendations
have also now fed into the process underway at the
European Commission to prepare the legal framework
for the implementation of the future ERNs, of which a
number, it is hoped, will be dedicated to rare diseases.
Stakeholders are now waiting for confirmation of how
the sustainability and designation of these ERNs will
be organised at European level. This question has been
partially answered by the mention of support for pro-
jects concerning the modelling and validation of system
methodologies for European Reference Networks in the
Horizon 2020 call [11] [Table 2].Patient registration and data collection: Gathering
information at European level on rare diseases
Patient registries are a key aspect of national plans/strat-
egies for rare diseases and are cited as a crucial source of
information on rare diseases, in terms of basic and clinical
research as well for epidemiological and public health pur-
poses, to be supported at national and European level in
the Council Recommendation. Patient registries are a key
tool for gathering the scarce knowledge relevant to rare
diseases so as to improve the understanding of these con-
ditions and the treatment available to patients, as well as
the planning of healthcare services for these diseases. Over
640 rare disease registries exist in Europe according to
data extracted from Orphanet [12] in December 2013,
with the majority concerning diseases of groups of dis-
eases for which there is an innovative treatment either in
development or already on the market. At the national
level many countries are considering in the scope of their
national plans/strategies the best way to collect data rela-
tive to rare disease patients, and at the Community level
the European Commission is in the process of establishing
a European Platform for Rare Disease Registration. The
EUCERD thus decided to build on the previous work of
the RDTF on patient registries to elaborate a set of Recom-
mendations on Rare Disease Patient Registration and Data
Collection [13] with the aim of setting down the consensus
reached to date and to guide all stakeholders at this crucial
moment in the collective reflection on the topic.
The EUCERD’s recommendations provide the consen-
sus to date in the field and call for the involvement of all
stakeholders in the designing, maintenance and govern-
ance of registries in the future, as well as public-private
partnerships for long-term sustainability. These recom-
mendations will serve all stakeholders in the field, in-
cluding Member States establishing their national plans/
strategies for rare diseases, the European Commission ser-
vices in their reflection on the sustainability of registries
for rare diseases at European level, and members of the
Industry looking to fulfil their post-market authorisation
obligations. These recommendations are also feeding into
discussions on data collection and registration underway
at international level in the working groups of the Inter-
national Rare Disease Research Consortium (IRDiRC) [14]
Table 4 Key facts and state of play in December 2013:
1
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for research purposes. Stakeholders at European and na-
tional level are now awaiting more information from the
Commission concerning the mission of the European plat-
form [Table 3].
Steps towards better and timely access to orphan
medicinal products for rare diseases : Improving the
Clinical Added Value of Orphan Medicinal Products
information flow
The EUCERD also worked, at the request of the European
Commission following a Tender report on the subject, on
the issue of equitable and timely access to approved or-
phan medicinal products for rare diseases. This matter is
highlighted by the Communication and Council Recom-
mendation where sharing of relevant knowledge is pro-
moted in order to “minimise delays in access to orphan
drugs for rare disease patients”. Although the European
Regulation on Orphan Medicinal Products (141/2000)
[15] establishes a centralised procedure for the designation
of orphan medicinal products and puts in place incentives
for the research, marketing and development of orphan
medicinal products, access to these medicines is often
difficult and unequal from country to country. In order
to advance the reflection on this matter, the EUCERD
brought together key stakeholders to discuss these issues
and adopted in 2012 a Recommendation on Improving In-
formed Decisions Based on the Clinical Added Value of
Orphan Medicinal Products Information Flow [16]. The
EUCERD’s recommendation highlights potential ways to
facilitate scientific information exchange in order to sup-
port Member States in their processes of making informed
decisions on the scientific assessment of the clinical effect-
iveness of an orphan medicinal product. The EUCERD
recommends creating an information flow between indi-
vidual Member States and between Member States and
EU bodies to bridge existing knowledge gaps, especially at
the time of market authorisation. Ultimately this will ac-
celerate access to approved orphan medicinal products by
providing the most robust set of information possible,
while encouraging pricing and reimbursement decisionsTable 3 Key facts and state of play in December 2013:
Rare disease patient registration and data collection
• Around 640 rare disease registries in Europe1
• Majority of registries are academic
• Some RD have more than one registry, many RD have no registry
• EUCERD Core Recommendations on Rare Disease Patient Registration
and Data Collection adopted on 5 June 2013
• Consensus on 6 main areas : international operability, sources of data,
collection of data, good practices, use of data for regulatory
purposes, and sustainability
1 Data as of December 2013 from Orphanet [www.orpha.net] concerning
European Member States and surrounding European countries in the
Orphanet Consortium.based on the value of these products and promoting good
medical practices throughout the EU. This recommenda-
tion is the fruit of dedicated participation from all stake-
holders, and has been warmly welcomed by across the
board. The EUCERD has submitted this proposal to the
European Commission in order to inform the next steps
in the process. Stakeholders now await further details con-
cerning pilot initiatives concerning suggested actions at
European level [Table 4].
Indicators for rare disease national plans/strategies :
Monitoring the progress made in national policy
To provide Member States elaborating their national
plans/strategies for rare diseases with guidance concern-
ing indicators to help monitor the elaboration and im-
plementation of these plans at European level, the
EUCERD has also adopted Recommendations on core in-
dicators for rare disease national plans/strategies (2013)
[17]. Indicators are vital tools for assessing the outcomes
and success of these measures. These indicators were
also intended to provide data for the European Commis-
sion’s report on the implementation of the Commission
Communication and Council Recommendation and to
serve as a basis for indicators at national level. Although
each country will have to tailor indicators to suit the
measures foreseen in their national plan/strategy, the
Recommendations may serve as a starting point for
some countries. They will be reviewed in time to reflect
the experience of Member States in the monitoring of
their plans/strategies.
Newborn screening: A definition of possible areas of
European collaboration
The EUCERD also decided to investigate areas of potential
collaboration at European level in the field of newborn
screening, at the request of the European Commission fol-
lowing a Tender report on the subject [18]. Currently, a
great heterogeneity of practices can be observed from
country to country in the EU and there is no systematicThe clinical added value of Orphan Medicinal Products
• 1234 positive opinions for orphan product designation from 1798
applications submitted since 2000 at EU level and a total of 1219
European Commission designations
• 85 orphan designated products have received marketing
authorisation by end of 2013 at EU level
• EUCERD Recommendation on Improving Informed Decisions Based
on the Clinical Added Value of Orphan Medicinal Products
Information Flow adopted in September 2012
• Recommendation proposes four key time points for information
sharing to improve the pricing and reimbursement decision process
1Data from the report of the European Medicines Agency's Committee on
Orphan Medicinal Products December 2013 [http://www.ema.europa.eu/docs/
en_GB/document_library/Committee_meeting_report/2014/01/WC500159429.
pdf].
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EUCERD took its cue from the Council Recommendation
encourages that Member States “develop European guide-
lines […] population screening, while respecting national
decisions and competences”. After examining the results
of the Tender study, the Committee was able to identify
a number of possible topics for collaboration which
respected the principle of subsidarity and after discussion
on the subject at Committee level an Opinion [19] was
adopted in July 2013. It was decided to not prioritise these
elements, which were submitted as an Opinion to the
European Commission, the Member States and third par-
ties for further consideration. This document is an im-
portant first step in this complicated area.
The EUCERD State of the Art Report: Monitoring progress
and reporting on initiatives
The EUCERD has played an important role in the moni-
toring and dissemination of the results of measures taken
at Community and national level in the field of rare dis-
eases, both through the annual report on the State of the
Art of Rare Disease Activities in Europe [20] and the bi-
monthly newsletter of the EUCERD OrphaNews Europe
[5]. The State of the Art report is a comprehensive docu-
ment updated each year which presents the current state
of activities at both European and Member State level in a
range of different areas of the rare disease field, such as
rare disease national plans/strategies, expert services, pa-
tient organisations, research and orphan medicinal prod-
uct policy. The first volume of the report presents an
overview of the field which presents to the general public
in an easily accessible manner the achievements to date
and challenges for the future, whereas the following vol-
umes present the environment in greater detail. The re-
port is also available in country-specific volumes for reuse
at national level to inform stakeholders of the state of play.
Both the report and the newsletter are supported by
the EUCERD Joint Action and entrusted to the Scientific
Secretariat of the EUCERD, with valuable contributions
and input from members of the Committee. Notably,
the information collected for the OrphaNews Europe
newsletter and State of Art report have contributed to
the preparation of the Commission reports on the im-
plementation of the Commission Communication and
Council Recommendation, currently underway. This re-
port from the Commission will help determine what has
been achieved to date and the measures to be taken in
the future in the field of rare diseases at European level.
Promoting cooperation across Europe and beyond
The EUCERD was also charged with assisting the Com-
mission in international cooperation on matters relating
to rare diseases. To this end, the EUCERD has wel-
comed representatives of third countries, such as Japan,to its meetings to partake in discussions and share expe-
riences. The EUCERD has also promoted liaison with
other groups implicated in the field of rare diseases (e.g.
IRDiRC [14], EUnetHTA [21], European Partnership Ac-
tion Against Cancer [22], PARENT Joint Action [23] by
inviting representatives to their meetings and including
them in expert workshops, as well as participating in
their meetings and workshops, to ensure that relevant
experience is shared across different groups and fields.
The EUCERD Joint Action is also working hard to liaise
with other EC-funded projects implicated in the field of
rare diseases to ensure that results are disseminated and
duplication of efforts are avoided.
Conclusion
The unique forum of stakeholders provided by the
EUCERD has been a key factor in the success of the
Committee in advancing discussions on important topics
for the rare disease community. The Members have
shown dedication and perseverance over the past three
years, helping the Committee to achieve much in a rela-
tively short space of time. Great advances have been
made in developing concepts, reaching consensus and
establishing recommendations for a number of key
topics which will be at the centre of national and Euro-
pean rare disease policy in the coming years. The suc-
cessful collaboration and outputs of the EUCERD is a
source of inspiration for countries and regions through-
out the world. The EUCERD has laid down the founda-
tions, but much more work is needed in the future as
we move from the stage of elaboration to the stage of
implementation of these initiatives and policies. It is
hoped that the European Commission Expert Group on
Rare Diseases, which replaces the EUCERD as of January
2014, will be as efficient and productive as the former
Committee in their new mandate so as to not lose the
momentum gathered under the EUCERD concerning
the main questions and problems faced by the rare dis-
ease community.
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